We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > MVR-T3011 IV

News List

ImmVira's MVR-T3011 IV completed first 2 cohorts dose-escalation of U.S. Phase I clinical study with favorable safety data prnasia
January 19, 2022
ImmVira's breakthrough product MVR-T3011 IV, global first clinical-stage oncolytic herpes simplex virus (oHSV) via intravenous injection, has recently completed first 2 cohorts dose-escalation of U.S. Phase I clinical study...
ImmVira's MVR-T3011 IV Completed First Dosing for Intravenous Administration in a U.S. Phase I Clinical Trial prnasia
August 11, 2021
ImmVira announced that it has initiated its lead oncolytic virus therapy program MVR-T3011 IV (also known as T3011). The first patient has been dosed, receiving MVR-T3011 intravenous (IV) administration in the U.S. on August 10, 2021.